Pramipexole Extended Release

DRUG4 trials

Sponsors

Boehringer Ingelheim

Conditions

HealthyParkinson Disease

Phase 1

Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers

CompletedNCT01214109

Boehringer IngelheimHealthy

Start: 2010-12-31Updated: 2014-06-27

Phase 2

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

CompletedNCT00560508

Boehringer IngelheimParkinson Disease

Start: 2007-11-30Updated: 2014-07-31

Phase 3

Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease

CompletedNCT00558025

Boehringer IngelheimParkinson Disease

Start: 2007-10-31Updated: 2014-05-16

Unknown Phase

Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease

CompletedNCT01097421

Boehringer IngelheimParkinson Disease

Start: 2010-03-31Updated: 2014-04-11